-
Add to Cart The item has been addedAb183321-5mgZilovertamab vedotin (anti-ROR1) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin (anti-ROR1) binding to tumor cell ROR1 -
Add to Cart The item has been addedAb183321-1mgZilovertamab vedotin (anti-ROR1) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin (anti-ROR1) binding to tumor cell ROR1 -
Add to Cart The item has been addedAb183321-10mgZilovertamab vedotin (anti-ROR1) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin (anti-ROR1) binding to tumor cell ROR1 -
Add to Cart The item has been addedAb183321-100μgZilovertamab vedotin (anti-ROR1) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin (anti-ROR1) binding to tumor cell ROR1 -
Add to Cart The item has been addedAb183037-5mgPritumumab (anti-Vimentin) is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab (anti-Vimentin) recognizes vimentin expressing on the cell surface of the malignant -
Add to Cart The item has been addedAb183037-1mgPritumumab (anti-Vimentin) is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab (anti-Vimentin) recognizes vimentin expressing on the cell surface of the malignant -
Add to Cart The item has been addedAb183037-10mgPritumumab (anti-Vimentin) is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab (anti-Vimentin) recognizes vimentin expressing on the cell surface of the malignant -
Add to Cart The item has been addedAb183037-100μgPritumumab (anti-Vimentin) is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab (anti-Vimentin) recognizes vimentin expressing on the cell surface of the malignant -
Add to Cart The item has been addedAb183026-5mgReslizumab (anti-IL-5) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab (anti-IL-5) is effective in neutralizing the function of IL-5. Reslizumab (anti-IL-5) has high binding -
Add to Cart The item has been addedAb183026-1mgReslizumab (anti-IL-5) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab (anti-IL-5) is effective in neutralizing the function of IL-5. Reslizumab (anti-IL-5) has high binding -
Add to Cart The item has been addedAb183026-10mgReslizumab (anti-IL-5) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab (anti-IL-5) is effective in neutralizing the function of IL-5. Reslizumab (anti-IL-5) has high binding -
Add to Cart The item has been addedAb183026-100μgReslizumab (anti-IL-5) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab (anti-IL-5) is effective in neutralizing the function of IL-5. Reslizumab (anti-IL-5) has high binding
